Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$25.99 USD
-0.57 (-2.15%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $25.98 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
SUPN 25.99 -0.57(-2.15%)
Will SUPN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SUPN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SUPN
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
SUPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
Other News for SUPN
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Sticks to Its Hold Rating for Supernus Pharmaceuticals (SUPN)
Piper Sandler Sticks to Its Buy Rating for Supernus Pharmaceuticals (SUPN)
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy